EFFECT OF HIGH-FLUX HEMODIALYSIS ON FGF23 LEVEL, CALCIUM-PHOSPHATE METABOLISM DISORDER, ARTERIOSCLEROSIS, AND CARDIAC FUNCTION IN PATIENTS WITH END-STAGE RENAL DISEASE

Objective: To observe the effects of high-flux haemodialysis (HFSD) on fibroblast growth factor 23 (FGF23) levels, calcium and phosphorus metabolism disorders, arteriosclerosis, and cardiac function in patients with end-stage renal disease (ESRD), and further clarify the advantages of HFSD in reducing the complications of ESRD. Methods: Sixty renal failure patients who underwent haemodialysis in our department of nephrology from October 2015 to October 2016 were randomly divided into the observation group and control group, with 30 cases in each group. The patients in the control group were given basic treatment and routine haemodialysis and the patients in the observation group underwent basic treatment and high-throughput haemodialysis. The changes in the FGF23 levels and the related indexes after two, four, and six months of treatment were observed. The carotid intima-media thickness (cIMT) and left ventricular ejection fraction (LVEF) before dialysis treatment and dialysis were observed. Results: After dialysis was completed, the serum P3(+) concentration of the two groups was lower than that before treatment, and the serum Ca2(+) concentration was negatively correlated with the P3(+) concentration. In the second month of dialysis, the serum Ca2(+) and P3(+) concentrations in the two groups were not significantly changed. In the fourth and sixth months of dialysis, the serum P3(+) concentration of the observation group was better than that of the control group, and the serum Ca2(+) concentration was better than the control group, the difference was statistically significant (P<0.05). In the second, fourth, and sixth months of the dialysis, the serum FGF23 concentration in the observation group was significantly lower than that in the control group, which was statistically significant (P<0.05). The cIMT and LVEF were lower in both groups after dialysis, and the observation group was superior to the control group (P<0.05). Conclusion: In patients with ESRD, HFHD can eliminate FGF23, correct calcium and phosphorus metabolism disorders, improve arteriosclerosis, and can improve cardiac function.